A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab.
Hiroki TanakaSoichiro YoshidaSatoru AoyamaSadakatsu IkedaJunko KuniedaKenichi OhashiShohei FukudaYuma WasedaHajime TanakaYasuhisa FujiiPublished in: IJU case reports (2024)
mutations and high tumor mutation burden.